REGAIP

AIP gene regulation and its implications in pituitary tumorigenesis

 Coordinatore QUEEN MARY UNIVERSITY OF LONDON 

 Organization address address: 327 MILE END ROAD
city: LONDON
postcode: E1 4NS

contact info
Titolo: Ms.
Nome: Tanya
Cognome: Szendeffy
Email: send email
Telefono: +44 20 7882 7260
Fax: +44 20 7882 7276

 Nazionalità Coordinatore United Kingdom [UK]
 Totale costo 209˙033 €
 EC contributo 209˙033 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2011-IEF
 Funding Scheme MC-IEF
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-05-01   -   2015-04-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    QUEEN MARY UNIVERSITY OF LONDON

 Organization address address: 327 MILE END ROAD
city: LONDON
postcode: E1 4NS

contact info
Titolo: Ms.
Nome: Tanya
Cognome: Szendeffy
Email: send email
Telefono: +44 20 7882 7260
Fax: +44 20 7882 7276

UK (LONDON) coordinator 209˙033.40

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

families    sporadic    pathological    disease    expression    adenomas    aip    transcription    promoter    penetrance    mutation    mirna    validation    regulation    species    adenoma    eqtls    fipa    patients    clinical    pituitary    mutations   

 Obiettivo del progetto (Objective)

'Background: Pituitary adenomas are a public health problem, due to their prevalence, morbidity and medical costs. AIP is a tumor suppressor gene that was recently linked to pituitary tumors in up to 30% of the familial isolated pituitary adenoma syndrome (FIPA) families, an autosomal dominant disease with incomplete penetrance. AIP mutation-positive patients are younger (children/young adults), have more aggressive disease, and respond less well to treatment than non-mutated patients. The mechanisms by which inactivating AIP mutations promote tumorigenesis remain unknown. Abnormal, mislocalised AIP expression in sporadic pituitary adenomas suggest a possible role in sporadic pituitary adenoma development as well. Very little is known about the normal and pathological regulation of AIP expression. Objective: To uncover major AIP transcription regulation by its canonical promoter, miRNA species and epistatic action of distant regulatory SNPs (eQTLs). Methods: 1) In vitro functional promoter dissection and identification of operating transcription factors and investigation of promoter mutations in FIPA families. 2) Screening and validation of miRNA species acting on AIP and study of their expression in pituitary adenomas and correlation with clinical / pathological features. 3) Detection and validation of AIP eQTLs and study of their implication in AIP mutation penetrance and their association with sporadic pituitary adenomas and their clinical/pathological features. Work programme relevance: Training through research in a major European pituitary centre will ensure development of essential experimental, theoretical and organizational skills of the fellow and will advance research at the host institution, thus improving quality of research at the ERA. The research results will have a significant impact not only on pituitary research, but also endocrinology (including pediatrics) and cancer research.'

Altri progetti dello stesso programma (FP7-PEOPLE)

NMS-CNT (2009)

Biocompatability of carbon nanoparticles with tissues of the neuromuscular system

Read More  

RECUP (2011)

Cryptographic Techniques for Reconciling Utility with Privacy in Computer Systems

Read More  

INTERMEDIUM (2014)

Increasing the genetic variation of wheat germplasm by introgressing Thinopyrum intermedium chromosomes and chromosome segments

Read More